BG103252A - The use of benzopyranols for the treatment of neurological disorders - Google Patents

The use of benzopyranols for the treatment of neurological disorders

Info

Publication number
BG103252A
BG103252A BG103252A BG10325299A BG103252A BG 103252 A BG103252 A BG 103252A BG 103252 A BG103252 A BG 103252A BG 10325299 A BG10325299 A BG 10325299A BG 103252 A BG103252 A BG 103252A
Authority
BG
Bulgaria
Prior art keywords
treatment
pains
benzopyranols
neurological disorders
neuralgia
Prior art date
Application number
BG103252A
Other languages
Bulgarian (bg)
English (en)
Inventor
Andrew Parsons
Mervyn Thompson
Neil Upton
Johan EVANS
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG103252A publication Critical patent/BG103252A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG103252A 1996-09-18 1999-03-15 The use of benzopyranols for the treatment of neurological disorders BG103252A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619492.3A GB9619492D0 (en) 1996-09-18 1996-09-18 Novel treatment
PCT/EP1997/005168 WO1998011890A1 (en) 1996-09-18 1997-09-15 Use of benzopyranols to treat neurological disorders

Publications (1)

Publication Number Publication Date
BG103252A true BG103252A (en) 1999-09-30

Family

ID=10800127

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103252A BG103252A (en) 1996-09-18 1999-03-15 The use of benzopyranols for the treatment of neurological disorders

Country Status (30)

Country Link
EP (1) EP0939630B1 (xx)
JP (1) JP2001500520A (xx)
KR (1) KR20000036184A (xx)
CN (1) CN1230885A (xx)
AP (1) AP9901473A0 (xx)
AR (1) AR008838A1 (xx)
AT (1) ATE270102T1 (xx)
AU (1) AU730465B2 (xx)
BG (1) BG103252A (xx)
BR (1) BR9712030A (xx)
CA (1) CA2266681A1 (xx)
DE (1) DE69729735T2 (xx)
DZ (1) DZ2311A1 (xx)
EA (1) EA199900306A1 (xx)
ES (1) ES2223075T3 (xx)
GB (1) GB9619492D0 (xx)
HU (1) HUP9904638A3 (xx)
ID (2) ID23175A (xx)
IL (1) IL128786A0 (xx)
MA (1) MA24321A1 (xx)
NO (1) NO991292D0 (xx)
NZ (1) NZ334271A (xx)
OA (1) OA10998A (xx)
PE (1) PE109898A1 (xx)
PL (1) PL332313A1 (xx)
SK (1) SK35199A3 (xx)
TR (1) TR199900527T2 (xx)
UY (1) UY24717A1 (xx)
WO (1) WO1998011890A1 (xx)
ZA (1) ZA978359B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
MX2010013312A (es) * 2008-06-05 2011-05-30 Minster Res Ltd Tratamientos novedoos.
MX2010013313A (es) * 2008-06-05 2011-05-30 Minster Res Ltd Tratamientos novedosos.
US8952034B2 (en) 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
MX2012006353A (es) * 2009-12-03 2012-06-27 Proximagen Ltd Tratamiento de enfermedades infecciosas.
US20130018091A1 (en) * 2009-12-03 2013-01-17 Peter Blower Treatment of allodynia and hyperalgesia
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
MX361350B (es) 2011-05-10 2018-12-04 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
NO3175985T3 (xx) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112721D0 (en) * 1991-06-13 1991-07-31 Smithkline Beecham Plc Novel treatment
US5510375A (en) * 1993-11-19 1996-04-23 Warner-Lambert Company Coumarin derivatives as protease inhibitors and antiviral agents
GB9411635D0 (en) * 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
CA2192480C (en) * 1994-06-10 2007-07-24 Wai Ngor Chan Benzopyrans and their use as therapeutic agents

Also Published As

Publication number Publication date
DE69729735T2 (de) 2005-07-14
EA199900306A1 (ru) 1999-08-26
CA2266681A1 (en) 1998-03-26
MA24321A1 (fr) 1998-04-01
CN1230885A (zh) 1999-10-06
NZ334271A (en) 2001-03-30
ATE270102T1 (de) 2004-07-15
GB9619492D0 (en) 1996-10-30
ZA978359B (en) 1999-03-17
NO991292L (no) 1999-03-17
NO991292D0 (no) 1999-03-17
PL332313A1 (en) 1999-08-30
KR20000036184A (ko) 2000-06-26
SK35199A3 (en) 2000-07-11
ID19542A (id) 1998-07-23
UY24717A1 (es) 2001-08-27
WO1998011890A1 (en) 1998-03-26
ES2223075T3 (es) 2005-02-16
JP2001500520A (ja) 2001-01-16
AR008838A1 (es) 2000-02-23
OA10998A (en) 2003-03-04
DE69729735D1 (de) 2004-08-05
PE109898A1 (es) 1999-03-21
DZ2311A1 (fr) 2002-12-28
BR9712030A (pt) 1999-08-24
EP0939630B1 (en) 2004-06-30
AU4704797A (en) 1998-04-14
HUP9904638A2 (hu) 2001-05-28
AP9901473A0 (en) 1999-03-31
EP0939630A1 (en) 1999-09-08
IL128786A0 (en) 2000-01-31
ID23175A (id) 2000-03-23
TR199900527T2 (xx) 1999-06-21
HUP9904638A3 (en) 2001-08-28
AU730465B2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
EP0792156A4 (en) METHOD FOR PREVENTING OR TREATING VASCULAR HEMORRAGIES AND ALZHEIMERIC DISEASE
ES2082887T3 (es) Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
GB0108592D0 (en) Therapeutic agents
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
FR2706767B1 (xx)
MXPA04004966A (es) Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
BG103252A (en) The use of benzopyranols for the treatment of neurological disorders
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AP1749A (en) Method of treating of demyelinating diseases or conditions.
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
WO2000021513A3 (en) Methods for treating multiple sclerosis
GB9425730D0 (en) Compounds
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
BG102079A (en) Alkylaminoderivatives of substituted quinoxalin-2,3-dions such as glutamatereceptor antagonists
WO2003020221A3 (en) Method of treating cancerous disease
ZA985668B (en) (S)-2-methylamino-2-phenyl-n-butyl 3,4,5-trimethoxy benzoate its application to the treatment of chronic pain
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
CA2138447A1 (en) Use of 2-Methylamino-2-Phenylcyclohexanone for the Treatment of Bacterial, Fungal, Virus or Protozoan Infections as Well as for Immunomodulation